Clinical Trials in Baltimore

Showing 21621-21640 of 23,476 trials

ETEC Logistics Trial (TREK)

NCT00516659

This is a multicenter, double-blind, randomized, placebo-controlled field trial to evaluate the epidemiology of natural infection with ETEC occurring after transcutaneous immunization in a field setting.

Diarrhea

Intercell USA, Inc.201 participantsStarted May 2006

Long Beach, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +16 more locations

COMPLETEDPhase 134 miles

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

NCT00091104

RATIONALE: Inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. Giving cyclophosphamide and fludarabine before a white blood cell infusion may suppress the immune system and allow tumor cells to be killed. Vaccines may make the body build an immune response to kill tumor cells. Aldesleukin may stimulate a person's white blood cells to kill tumor cells. Combining white blood cell infusion with vaccine therapy and aldesleukin may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gene-modified white blood cells when given together with cyclophosphamide, fludarabine, vaccine therapy, and aldesleukin and to see how well it works in treating patients with metastatic melanoma.

Melanoma (Skin)

National Institutes of Health Clinical Center (CC)136 participantsStarted Jul 2004

Bethesda, Maryland, United States • Bethesda, Maryland, United States

ETEC Logistics Trial (TREK)

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Find Trials by Condition in Baltimore

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome

Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

ABT-751 in Treating Young Patients With Refractory Solid Tumors

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors

Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study